---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115735"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:33:37.552950+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Natera Q3 revenue $268.3M (+27% YoY), raises FY2023 revenue and margin guidance, reduces cash burn

## Summary
- Revenue $268.3M, up 27% YoY; product revenue $265.2M, up 33% YoY.
- Processed ~626,000 tests (+21% YoY); oncology tests ~89,000 (+68% YoY) with 81,000 Signatera clinical units (+85%).
- Net loss improved to $109.0M ($0.95/share) from $121.5M ($1.25/share) in Q3 2022.
- Raises 2023 revenue guidance to $1.035B-$1.05B (from $1.015B-$1.035B); cash burn reduced to $260M-$280M (from $300M-$325M).
- Cash, equivalents and investments $936.6M; total debt $363.0M.

## SEC filing metadata
- accession: 0001104659-23-115735
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/0001104659-23-115735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/tm2329774d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115735
- JSON: https://secwatch.observer/filing/0001104659-23-115735.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115735.txt

## Key facts
- Earnings Releases
  Natera, Inc. reported third quarter ended September 30, 2023 results: revenue $268.3 million, net income net loss of $109.0 million, EPS ($0.95) per diluted share. Guidance raised.
  - Period: third quarter ended September 30, 2023
  - Revenue: $268.3 million
  - Net income: net loss of $109.0 million
  - EPS: ($0.95) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: cell-free DNA testing , today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210.6 million in the third quarter of 2022, an increase of approximately 27%. Product revenues grew approximately 33% over the same
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/0001104659-23-115735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.